These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 16981802

  • 21. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
    Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ.
    J Clin Oncol; 2015 Jul 01; 33(19):2190-6. PubMed ID: 25987701
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG.
    Arch Gen Psychiatry; 2005 Apr 01; 62(4):435-41. PubMed ID: 15809411
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul 15; 877(22):1982-96. PubMed ID: 19505856
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
    Timmers L, Beckeringh JJ, van Herk-Sukel MP, Boven E, Hugtenburg JG.
    Pharmacoepidemiol Drug Saf; 2012 Oct 15; 21(10):1036-44. PubMed ID: 21956857
    [Abstract] [Full Text] [Related]

  • 31. Reduced medical spending associated with integrated pharmacy benefits.
    Lucas E, Liu M, Ouyang J, Vicidomina B, Ford M, Keller BP, Nigam S.
    Am J Manag Care; 2021 Jul 01; 27(7):e242-e247. PubMed ID: 34314125
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
    MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J.
    J Manag Care Spec Pharm; 2016 Aug 01; 22(8):979-90. PubMed ID: 27459661
    [Abstract] [Full Text] [Related]

  • 34. Drug super spender tsunami: An integrated medical and pharmacy benefits assessment.
    Starner CI, Bowen K, Gleason PP.
    J Manag Care Spec Pharm; 2022 Nov 01; 28(11):1200-1206. PubMed ID: 36282927
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
    Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock SJ.
    Curr Med Res Opin; 2015 Feb 01; 31(2):289-97. PubMed ID: 25420131
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD, Clarke L, Kamath TV, Lubeck D.
    J Manag Care Pharm; 2006 Feb 01; 12(6):472-8. PubMed ID: 16925455
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.